Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | P2RY12 | Q9H244 | 6/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | DHODH | Q02127 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30420698 | 0.89 | ALOX15 (0.80) | ALOX15ALDH1A1GPR35LMNAHPGD | |
| SCHEMBL10202005 | 0.89 | ALOX15 (0.79) | ALOX15ALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL6387003 | 0.87 | ALOX15 (0.77) | ALOX15ALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL27467736 | 0.87 | ALOX15 (0.77) | ALOX15ALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL13075989 | 0.87 | ALOX15 (0.77) | ALOX15ALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL31389251 | 0.87 | ALOX15 (0.77) | ALOX15ALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL2072605 | 0.87 | ALOX15 (0.77) | ALOX15ALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL4409321 | 0.87 | ALOX15 (0.77) | ALOX15ALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL12256861 | 0.87 | ALOX15 (0.77) | ALOX15ALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL8569893 | 0.84 | ALOX15 (0.73) | ALOX15ALDH1A1LMNAHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 311 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111295382-B | Bridged bicyclic compounds as farnesyl ester X receptor modulators | 百时美施贵宝公司 | 2024-02-02 | — | — | CN | claimed |
| CN-111511731-B | Olefin compounds as modulators of the farnesol X receptor | 百时美施贵宝公司 | 2023-05-23 | — | — | CN | claimed |
| CN-111278817-B | Polycyclic compounds as farnesol X receptor modulators | 百时美施贵宝公司 | 2023-05-16 | — | — | CN | claimed |
| EP-2069289-B1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS | SANOFI SA (FR) | 2013-10-02 | — | — | EP | claimed |
| US-8288435-B2 | 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-10-16 | — | — | US | claimed |
| EP-2079690-B1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-15 | — | — | EP | claimed |
| EP-1678162-B1 | P-GLYCOPROTEIN INHIBITOR, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HANMI PHARM IND CO LTD (KR) | 2010-04-28 | — | — | EP | claimed |
| US-20100016401-A1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | Actelion Phamaceuticals Ltd. (CH) | 2010-01-21 | — | — | US | claimed |
| US-7625926-B2 | P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same | HANMI PHARM. CO., LTD (KR) | 2009-12-01 | — | — | US | claimed |
| EP-2121635-A2 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | Sanofi-Aventis (FR) | 2009-11-25 | — | — | EP | claimed |
| WO-1998033786-A1 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-08-06 | — | — | WO | claimed |
| WO-1998002741-A9 | QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES | — | 1998-05-22 | — | — | WO | claimed |
| WO-1998002741-A1 | QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-01-22 | — | — | WO | claimed |
| US-5657064-A | Recording sheets containing pyrrole, pyrrolidine, pyridine, piperidine, homopiperidine, quinoline, isoquinoline, quinuclidine, indole, and indazole compounds | XEROX CORPORATION (US) | 1997-08-12 | — | — | US | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| EP-0673782-A2 | Recording sheets containing pyrrole, pyrrolidine, pyridine, piperidine, homopiperidine, quinoline, isoquinoline, quinuclidine, indole, and indazole compounds | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | claimed |
| EP-0564676-A1 | Light polarizing material based on quinaldic acid derivatives | RESEARCH FRONTIERS INCORPORATED (US) | 1993-10-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016401-A1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | HCRTR1, HCRTR2, CNR1 | ALOX15 433/4885ALDH1A1 702/4885GPR35 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.